Press Releases

AstraZeneca announced that it has completed the licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic (lesinurad) and the fixed-dose combination of lesinurad and allopurinol. Zurampic is approved in the US, in combination...

Shire plc completed its previously announced combination with Baxalta Incorporated ,creating the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions. Through the combination, Shire expects to deliver double-digit...

Mylan N.V. announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for...

Contract Manufacturing Revenue Hits All-Time High of $44 Million for Fiscal Year Ended April 2016; Fiscal Year 2017 Contract Manufacturing Revenue Projected Between $50-55 Million; Continued Growth Expected to Lead to Future Sustainable Profitability in 24 Months ...

Novartis announced that the EU has approved Afinitor®(everolimus) tablets for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin in adults with progressive disease. ...

Study will include patients with Stage IIIB and IIIC colon cancer who have undergone complete surgical resection of primary tumor and received standard adjuvant chemotherapy / Indication-seeking trial will be conducted by NSABP with the support from Bayer. ...

Allergan plc a leading global pharmaceutical company announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLBELLA®XC, for use in the lips for lip augmentation and for correction of perioral...